Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

NCT00636168 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1211

Enrollment

INDUSTRY

Sponsor class

Conditions

High Risk Stage III Melanoma

Interventions

DRUG: ipilimumab
DRUG: Placebo

Sponsor

Bristol-Myers Squibb